Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Jusko WJ and D'Ambrosio R | Monitoring FK 506 concentrations in plasma and whole blood. | 1991 | Transplant. Proc. | pmid:1721260 |
Venkataramanan R et al. | Pharmacokinetics of FK 506 in transplant patients. | 1991 | Transplant. Proc. | pmid:1721261 |
Christians U et al. | High performance liquid chromatography/mass spectrometry of FK 506 and its metabolites in blood, bile, and urine of liver grafted patients. | 1991 | Transplant. Proc. | pmid:1721262 |
Beysens AJ et al. | FK 506: monitoring in plasma or in whole blood? | 1991 | Transplant. Proc. | pmid:1721263 |
Akselband Y et al. | Rapamycin inhibits spontaneous and fibroblast growth factor beta-stimulated proliferation of endothelial cells and fibroblasts. | 1991 | Transplant. Proc. | pmid:1721292 |
Schreiber SL et al. | Immunophilin-ligand complexes as probes of intracellular signaling pathways. | 1991 | Transplant. Proc. | pmid:1721293 |
Ullman KS et al. | Site of action of cyclosporine and FK 506 in the pathways of communication between the T-lymphocyte antigen receptor and the early activation genes. | 1991 | Transplant. Proc. | pmid:1721294 |
Sigal NH et al. | Is FKBP involved in the immunosuppressive and/or toxic mechanism of action of FK 506? | 1991 | Transplant. Proc. | pmid:1721295 |
Jordan ML et al. | Inhibition of T-cell function by FK 506 and cyclosporine is not accompanied by alterations in intracellular calcium. | 1991 | Transplant. Proc. | pmid:1721323 |
Motta I et al. | FK 506 favors the generation of memory T cells in vitro. | 1991 | Transplant. Proc. | pmid:1721324 |
Nakata S et al. | Immunosuppressive effect of FK 506 on cytotoxic T lymphocytes and delayed-type hypersensitivity in rats. | 1991 | Transplant. Proc. | pmid:1721325 |
Cooper MH et al. | Evaluation of the influence of FK 506, rapamycin, and cyclosporine on processing and presentation of particulate antigen by macrophages: assessment of a drug "carry-over" effect. | 1991 | Transplant. Proc. | pmid:1721326 |
Whiteside TL et al. | Serial monitoring of immunologic function and phenotype of lymphocytes in the blood of transplanted patients randomized to cyclosporine or FK 506. | 1991 | Transplant. Proc. | pmid:1721356 |
Frayha HH et al. | Lymphoproliferative disorder in a liver transplant patient on FK 506. | 1991 | Lancet | pmid:1703258 |
Van Thiel DH et al. | Interferon therapy of hepatitis following liver transplantation under FK 506 or cyclosporine. | 1991 | Transplant. Proc. | pmid:1721357 |
Burman K and Crawford DH | Effect of FK 506 on Epstein-Barr virus specific cytotoxic T cells. | 1991 | Lancet | pmid:1703259 |
Armitage JM et al. | The clinical trial of FK 506 as primary and rescue immunosuppression in adult cardiac transplantation. | 1991 | Transplant. Proc. | pmid:1721358 |
Nalesnik MA et al. | Lymphoproliferative disorders arising under immunosuppression with FK 506: initial observations in a large transplant population. | 1991 | Transplant. Proc. | pmid:1703335 |
Armitage JM et al. | The clinical trial of FK 506 as primary and rescue immunosuppression in pediatric cardiac transplantation. | 1991 | Transplant. Proc. | pmid:1721359 |
Armitage JM et al. | A clinical trial of FK 506 as primary and rescue immunosuppression in cardiac transplantation. | 1991 | Transplant. Proc. | pmid:1703336 |
Winkler M et al. | Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients. | 1991 | Transplant. Proc. | pmid:1721389 |
Schmidt RJ et al. | Hemolytic-uremic syndrome in a renal transplant recipient on FK 506 immunosuppression. | 1991 | Transplant. Proc. | pmid:1721390 |
Tze WJ et al. | Effect of FK 506 on glucose metabolism and insulin secretion in normal rats. | 1991 | Transplant. Proc. | pmid:1721391 |
Doi R et al. | Mechanisms by which FK 506 affects exocrine pancreas in rats. | 1991 | Transplant. Proc. | pmid:1721392 |
Steinmann B et al. | Mechanism of action of FK 506 and cyclosporin. | 1991 | Lancet | pmid:1704088 |
Markus PM et al. | The effect of cyclosporine, rapamycin and FK 506 the survival following allogeneic bone marrow transplantation. | 1991 | Transplant. Proc. | pmid:1721418 |
Cooper MH et al. | The induction of pseudo-graft-versus-host disease following syngeneic bone marrow transplantation using FK 506. | 1991 | Transplant. Proc. | pmid:1721419 |
Boggs S et al. | FK 506 has no short-term effects on endogenous or exogenous myeloid reconstitution in irradiated mice. | 1991 | Transplant. Proc. | pmid:1721420 |
Cooper MH et al. | Prolonged prevention of acute graft-versus-host disease after allogeneic bone marrow transplantation by donor pretreatment using FK 506. | 1991 | Transplant. Proc. | pmid:1721421 |
Yoshimi F et al. | Canine total orthotopic small bowel transplantation under FK 506. | 1991 | Transplant. Proc. | pmid:1721422 |
Stevens C et al. | The effects of immunosuppressive agents on in vitro production of human immunoglobulins. | 1991 | Transplantation | pmid:1710843 |
Metcalfe S and Milner J | Evidence that FK506 and rapamycin block T cell activation at different sites relative to early reversible phosphorylation involving the protein phosphatases PP1 and PP2A. | 1991 | Transplantation | pmid:1710844 |
Chang JY et al. | FK506 and rapamycin: novel pharmacological probes of the immune response. | 1991 | Trends Pharmacol. Sci. | pmid:1710854 |
Neuberger J | FK 506--a promise of good things to come? | 1991 | Hepatology | pmid:1711005 |
Halloran PF and Madrenas J | The mechanism of action of cyclosporine: a perspective for the 90's. | 1991 | Clin. Biochem. | pmid:1711939 |
Abu-Elmagd K et al. | Efficacy of FK 506 in the treatment of recalcitrant pyoderma gangrenosum. | 1991 | Transplant. Proc. | pmid:1721451 |
Thomson AW et al. | Influence of FK 506 on T lymphocytes, Langerhans' cells and the expression of cytokine receptors and adhesion molecules in psoriatic skin lesions: a preliminary study. | 1991 | Transplant. Proc. | pmid:1721452 |
Sainsbury TS et al. | Differential effects of FK 506 and cyclosporine on hair regrowth in the DEBR model of alopecia areata. | 1991 | Transplant. Proc. | pmid:1721453 |
Fujino Y et al. | FK 506 treatment of experimental autoimmune uveoretinitis in primates. | 1991 | Transplant. Proc. | pmid:1721454 |
Christians U et al. | Isolation of an immunosuppressive metabolite of FK506 generated by human microsome preparations. | 1991 | Clin. Biochem. | pmid:1714802 |
Turka LA and Thompson CB | Structure-function relationship of immunosuppressive drugs: a cautionary tale. | 1991 | Hepatology | pmid:1714876 |
Brizuela L et al. | Antifungal properties of the immunosuppressant FK-506: identification of an FK-506-responsive yeast gene distinct from FKB1. | 1991 | Mol. Cell. Biol. | pmid:1715022 |
Heitman J et al. | Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. | 1991 | Science | pmid:1715094 |
Fung JJ et al. | Conversion of liver allograft recipients from cyclosporine to FK 506-based immunosuppression: benefits and pitfalls. | 1991 | Transplant. Proc. | pmid:1703682 |
Marquis-Omer D et al. | Stabilization of the FK506 binding protein by ligand binding. | 1991 | Biochem. Biophys. Res. Commun. | pmid:1716886 |
Wu J et al. | Comparative immunoregulatory effects of rapamycin, FK 506 and cyclosporine on mitogen-induced cytokine production and lymphoproliferation. | 1991 | Transplant. Proc. | pmid:1703683 |
Sakai K et al. | [The effect of a new immunosuppressive agent, FK-506, on xenogeneic neural transplantation in rodents--comparison with cyclosporin A]. | 1991 | No To Shinkei | pmid:1716937 |
Yoshimura R et al. | A comparative study between cyclosporine and FK 506 effects on renal microsomal P-450. | 1991 | Transplant. Proc. | pmid:1703686 |
Miyagawa S et al. | Mechanism of unresponsiveness in rats induced by a short course of FK 506 or CyA. | 1991 | Transplant. Proc. | pmid:1703687 |
Fujino Y et al. | FK506 treatment of S-antigen induced uveitis in primates. | 1991 | Curr. Eye Res. | pmid:1717199 |